CANDEL THERAPEUTICS CADL 深 沪
已收盘 08-29 16:00:00 美东时间
5.79
-0.030
-0.52%
华盛通- 最 高5.92
- 今 开5.85
- 成交量 32.91万股
- 最 低 5.70
- 昨 收 5.82
- 总市值 3.18亿
- 52周最高 14.60
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 3.785
- 委 比 -54.74%
- 总股本 5489.51万
- 历史最高 14.78
- 量 比 0.70
- 振 幅 3.78%
- 历史最低 0.66
- 每 手 1
- 风险率 3.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Candel Therapeutics to Participate in Upcoming Investor Conferences in September
Candel Therapeutics announced that its CEO, Paul Peter Tak, will participate in several investor conferences in September 2025, including Citigroup's Biopharma Back to School Conference in Boston, the Cantor Global Healthcare Conference in New York, and the H.C. Wainwright Global Investment Conference in New York. Each event will feature live webcasts accessible via the company's website. Candel, a clinical-stage biopharmaceutical company, focuse...
08-28 12:05
Candel Therapeutics Extends Lease Agreement in Needham
Candel Therapeutics ( ($CADL) ) has issued an announcement. On August 18, 2025,...
08-22 05:01
Candel Therapeutics Advances with Promising Cancer Therapies
Candel Therapeutics, Inc. ( ($CADL) ) has released its Q2 earnings. Here is a b...
08-19 12:09
Candel Therapeutics Q2 EPS $(0.09) Beats $(0.17) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.17) by 46.43 percent. This is a 87.84 percent increase over losses of $(0.74) per share
08-14 20:29
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics announced positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer and received FDA's RMAT designation. The company also reported financials with $100.7 million in cash, tracking toward a Q4 2026 BLA submission. CAN-2409 showed promising outcomes in prostate, pancreatic, and lung cancers, with extended survival rates. Candel appointed new leadership and completed a registered direct offering to support p...
08-14 12:05
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Candel Therapeutics的CEO Paul Peter Tak将在Canaccord Genuity的会议上发言，探讨其多模式生物免疫疗法在癌症治疗中的进展。Candel专注于开发基于腺病毒和HSV的免疫疗法，其主要产品CAN-2409在前列腺癌和肺癌等适应症中取得进展，并获得FDA的RMAT和Fast Track认定。CAN-3110则针对脑瘤，正处于临床试验阶段。会议将于8月13日线上直播。
07-30 12:05
Candel Therapeutics Secures EMA Orphan Designation For CAN-2409 For Treatment Of Pancreatic Cancer
andel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that
07-24 20:07
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the S&P 500 futur...
07-16 20:28
Candel Therapeutics Added To Multiple Russell Value Indexes In 2025 Reconstitution
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that
07-09 20:09
